Prophylactic Efmoroctocog Alfa may improve outcomes in patients with hemophilia A: Study

A recent retrospective study published in the journal of Hematology explored the clinical characteristics and treatment patterns of patients with hemophilia A who were undergoing prophylactic treatment. This comprehensive study utilized data from the Systeme National des Donnees de Sante database which spanned from 2016 to 2019 to highlight the factors such as factor consumption and events of interest in this patient population. This study also evaluated the clinical impact of transitioning these patients to Elocta® which is an extended half-life treatment for hemophilia A.

Among the 545 patients included in the analysis, Elocta® emerged as the most frequently utilized treatment option. The bleeding events affected 15.4% of patients, while 13.9% experienced articular non-bleeding events leading to hospitalization. The surgeries or procedures related to hemophilic arthropathy were reported in 9.9% of cases. The outcomes revealed a mean monthly factor VIII product consumption of 344 IU/kg/month for extended half-life treatment and 331 IU/kg/month for standard half-life products.